Site Search
Displaying results 31 - 40 of 573
Resource | Publications,
Member states recognized the need for all countries to have unhindered, timely access to quality, safe, efficacious and affordable diagnostics, therapeutics, medicines and vaccines, and essential health technologies despite challenges faced during COVID-19. Progress has been made in the areas of medicine pricing policies, transparency in decision-making processes, building resilient supply chains, and strengthening of National Medicines Regulatory Authorities (NMRA)s through South-East Asia Regulatory Network (SEARN).
Resource | Presentations,
Browse and view tables, charts and graphs illustrating data on key populations, HIV prevalence and epidemiology, risk behaviors, gender-based violence, HIV knowledge, HIV expenditures, country responses, and treatment.
Resource | Publications,
The new and updated WHO recommendations are intended to support countries to scale up access to and uptake of cervical cancer screening and treatment with quality modern technologies and thereby improve coverage of both screening and treatment and reduce cervical cancer disease and deaths.
This policy brief highlights the key features of the new recommendations on screening and treatment for cervical pre-cancer among women living with HIV, and includes programme considerations for implementation including service delivery, service integration and addressing barriers to access.
Resource | Guidelines,
These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic recommendations across different ages, populations and settings, bringing together all relevant WHO guidance on HIV produced since 2016. It serves as an update to the previous edition of the consolidated guidelines on HIV.
These guidelines continue to be structured along the continuum of HIV care. Information on new combination prevention approaches, HIV testing, ARV regimens and treatment monitoring are included. There is a new chapter on advanced HIV disease that integrates updated guidance on the management of important HIV comorbidities, including cryptococcal disease, histoplasmosis and tuberculosis. The chapter on general HIV care, contains a new section on palliative care and pain management, and up to date information on treatment of several neglected tropical diseases, such as visceral leishmaniasis and Buruli ulcer. New recommendations for screening and treating of cervical pre-cancer lesions in women living with HIV are also addressed in this chapter.
Resource | Publications,
WHO has set a global goal to eliminate HCV as a public health problem by 2030. WHO estimates that 58 million people had chronic hepatitis C virus (HCV) infection globally in 2019, and less than a quarter of them were diagnosed. New and innovative approaches are needed to accelerate progress toward the HCV elimination targets. Self-testing is one such approach.
These guidelines provide a new recommendation and guidance on HCV self-testing to complement existing HCV testing services in countries. These guidelines also highlight operational considerations to support strategic implementation and scale up of HCV self-testing.
Resource | Publications,
This report highlights several challenges faced by people living with HIV in the country across the HIV care continuum. Issues on various facets of HIV care continuum such as access to HIV facilities and psychosocial support are surfaced and discussed. Policy and program recommendations that will help the in development of the national HIV program that is more robust, with or without the threats of COVID-19, are also presented.
Resource | Publications,
To maximise the benefits of COVID-19 vaccines, urgent efforts are needed to achieve greater vaccine equity. Addressing the known and emerging gender-related inequities is critical. This Guidance Note and Checklist provide a set of practical actions for countries to advance gender equality and equity in the deployment of COVID-19 vaccines.
Resource | Publications,
WHO has developed this interim guidance for countries and other stakeholders seeking validation of elimination of viral hepatitis as a public health problem, with a specific focus on hepatitis B virus (HBV) and hepatitis C virus (HCV). It provides a global framework for the processes and standards for validation of elimination, and overall proposes the use of absolute impact targets to validate elimination at the national level (instead of, although equivalent to, the relative reduction targets originally defined in the 2016 GHSS) in combination with a set of programmatic targets.
Resource | Publications,
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth GLASS report.
The fourth GLASS report summarizes the 2019 data reported to WHO in 2020. It includes data on AMC surveillance from 15 countries and AMR data on 3 106 602 laboratory-confirmed infections reported by 24 803 surveillance sites in 70 countries, compared to the 507 923 infections and 729 surveillance sites reporting to the first data call in 2017.
The report also describes developments over the past years of GLASS and other AMR surveillance programmes led by WHO, including resistance to anti-human immunodeficiency virus and anti-tuberculosis medicines, antimalarial drug efficacy.
Resource | Publications,
This report provides accountability for the 3 Global Health Sector Strategies (2016-2021) on HIV, Viral Hepatitis and the STIs. The report assesses the impact, progress and gaps, and identifies actions to improve impact. The report also provides new data to assess the achievement of the SDGs targets and gaps towards the Thirteenth General Programme of Work (GPW 13) targets and a decade towards elimination.
The report describes WHO’s important contributions at regional and global level and identifies common actions across the 3 disease areas as well as gaps and priorities as a baseline for the next strategies.
More specifically, the report reviews progress in the health sector response along each of the strategy’s strategic directions, and in each WHO region, and discusses the opportunities for overcoming the remaining challenges to achieve universal access to effective HIV/STI/Hepatitis interventions and for contributing to the broader goal of universal health coverage.